All In Biotech

NDA 020428 · Almirall

Azelex

Azelaic Acid · Topical

Novel

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Sep 13, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

37

9 Phase 3, 1 recruiting

FAERS reports

977

510 serious, 86 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2026.

INDICATIONS AND USAGE AZELEX ® cream is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 13, 1995 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • AZELEX · AZELAIC ACID 20% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Azelaic Acid" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective172
  • pain142
  • off label use125
  • vomiting113
  • abdominal pain upper111
  • rash108
  • product use in unapproved indication107
  • gastrooesophageal reflux disease104
  • migraine104
  • paraesthesia103
  • memory impairment100
  • hypoaesthesia99

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
20051
20063
20071
20087
20099
201015
20116
201218
201310
201415
201527
201629
201719
201830
201939
202065
202180
202270
202388
2024139
2025146
2026155

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azelex (Azelaic Acid)

2024 spending

$1.5M

Beneficiaries

1,175

2,095 claims

Per beneficiary

$1,247

$16.30 per unit

View as table
YearSpending
2020$1,068,798
2021$1,378,645
2022$1,395,398
2023$1,511,623
2024$1,465,383

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 108 on PubMed

Sponsor: Almirall

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.